Patents Represented by Attorney E. Anthony Figg
  • Patent number: 5024669
    Abstract: A multilayered or tubular, woven artificial ligament contains distinct regions, each of which has physical properties suited to the function to be served. An intra-articular region is characterized by a woven structure, a high elongation under load and a degree of elasticity, similar to that of natural ligaments. A region which resides in a tunnel bored into a bone is characterized by a low elongation under load and a degree of porosity which promotes boney attachment of the ligament to the host bone. The artificial ligaments are woven from low elongation yarns, and the properties of the different regions of the ligaments are achieved through careful control of the weaving conditions and post-weaving, heat-setting treatments.
    Type: Grant
    Filed: September 9, 1988
    Date of Patent: June 18, 1991
    Assignee: Baxter International Inc.
    Inventors: Robert H. Peterson, Erin McGurk-Burleson
  • Patent number: 4838888
    Abstract: A process for treating biological tissue prior to implantation to mitigate the calcification of the tissue following implantation comprises incorporating acetylsalicylic acid into the tissue in an amount effective to reduce calcification of the tissue after it is implanted. In accordance with one embodiment, the process involves convalently binding the acetylsalicylic acid to the tissue via a coupling agent.
    Type: Grant
    Filed: April 17, 1987
    Date of Patent: June 13, 1989
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Aws S. Nashef
  • Patent number: 4559359
    Abstract: A method for the treatment of glaucoma or lowering intraocular pressure in a mammal, involving topically administering to the eye of such mammal a selectively metabolized beta-blocking compound of the formula: ##STR1## wherein Ar may be substituted or unsubstituted aromatic, Y may be a straight or branched carbon chain or aralkyl, R may be lower alkyl, lower alkenyl, lower alkynyl, aryl, or aralkyl, and x is an integer from 1 to about 3; or a pharmaceutically acceptable salt thereof. Because of a relatively long duration of action of such compounds in ocular fluids and a relatively short duration of action in the systemic circulation, such compounds are useful for the treatment of excessive intraocular pressure without substantial systemic effects.
    Type: Grant
    Filed: May 29, 1984
    Date of Patent: December 17, 1985
    Assignee: American Hospital Supply Corporation
    Inventor: William L. Matier